Revolution Medicines, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDRevolution Medicines, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 95), indicating clear outperformance against the broad market. Earnings contraction of 68% provides fundamental context to the price action. Investors should exercise caution due to high volatility (56% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $99.05 | +3.00% | ABOVE |
| 50 SMA | $98.48 | +3.60% | ABOVE |
| 100 SMA | $81.43 | +25.29% | ABOVE |
| 150 SMA | $67.68 | +50.73% | ABOVE |
| 200 SMA | $60.50 | +68.64% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is RVMD in an uptrend right now?
RVMD has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, RVMD is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is RVMD overbought or oversold?
RVMD's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is RVMD outperforming the market?
RVMD has a Relative Strength (RS) Rating of 95 out of 99. Yes, RVMD is a market leader, outperforming 95% of all stocks over the past 12 months.
Where is RVMD in its 52-week range?
RVMD is trading at $102.02, which is 82% of its 52-week high ($124.49) and 76% above its 52-week low ($29.17).
How volatile is RVMD?
RVMD has a Beta of 0.99 and 52-week volatility of 56%. It's less volatile than the S&P 500 - generally more stable.